Active Stocks
Tue Apr 16 2024 15:59:30
  1. Tata Steel share price
  2. 160.05 -0.53%
  1. Infosys share price
  2. 1,414.75 -3.65%
  1. NTPC share price
  2. 359.40 -0.54%
  1. State Bank Of India share price
  2. 751.90 -0.65%
  1. HDFC Bank share price
  2. 1,509.40 0.97%
Business News/ Companies / News/  Cipla launches polymerase chain reaction test kit ‘ViraGen’ for Covid-19
BackBack

Cipla launches polymerase chain reaction test kit ‘ViraGen’ for Covid-19

ViraGen is a real-time detection kit approved by the Indian Council of Medical Research and is based on multiplex PCR technology.

FILE PHOTO: Employees and security staff work at the reception area of Cipla at its headquarters in Mumbai, India (REUTERS)Premium
FILE PHOTO: Employees and security staff work at the reception area of Cipla at its headquarters in Mumbai, India (REUTERS)

Cipla Limited has launched ‘ViraGen’, a polymerase chain reaction (Covid-19 RT-PCR) test for Covid-19 in India. The pharma company on Thursday announced the commercialisation of test kit ‘ViraGen’ in partnership with Ubio Biotechnology Systems Pvt. Ltd.

ViraGen is the company's third offering in the Covid-19 testing segment. Cipla already has partnerships for antibody detection kit and antigen test, it said in an exchange filing.

ViraGen is a real-time detection kit approved by the ICMR (Indian Council of Medical Research) and is based on multiplex PCR technology. It helps to identify and detect SARS CoV-2 N Gene and ORF Lab Gene with the sensitivity of 98.6% and the specificity of 98.8% as compared to a standard ICMR test.

This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19.

ViraGen used for qualitative detection of SARS-CoV-2 will be manufactured by Ubio Biotechnology Systems and marketed and distributed by Cipla through its expansive distribution network across the country, the company added.

Cipla said that this launch will help address the current testing services and capacity issues while reaffirming the Company’s ongoing expansion in the diagnostic space. The company will commence supply of the detection kit from May 25, 2021.

Commenting on the partnership, Umang Vohra, MD & Global CEO, Cipla, said, “Cipla has been working relentlessly to ensure accessibility to treatments in this fight against COVID-19. Guided by our core purpose of ‘Caring for Life’, this partnership will enable us to reach out to more people across the country at a crucial time like now.''

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 20 May 2021, 09:03 AM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App